Blog | BioInformant

NeuroSense’s PrimeC Shows Compelling Results for ALS Survival in Novel iPSC Model

October 9, 2023 By Cade Hildreth, Founder & President Leave a Comment

Key Points:

Groundbreaking study utilized iPSCs derived from blood samples of ALS patients to evaluate the survival rate of induced motor neurons when treated with NeuroSense’s product candidate, PrimeC.

In collaboration with the University of Southern California’s Ichida Stem Cell Lab, PrimeC significantly increased the survival rate of induced motor neurons in an in vitro study iPSCs generated from people living with ALS.

In a groundbreaking collaborative effort, NeuroSense Therapeutics Ltd. announced the results of a recent study that could be life-changing for those suffering from amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study, conducted by Dr. Justin Ichida at the University of Southern California’s Stem Cell Ichida Lab, has shown that NeuroSense’s PrimeC significantly increased the survival rate of induced motor neurons in an innovative in vitro model using induced pluripotent stem cells (iPSCs) derived from ALS patients. This discovery has the potential to revolutionize ALS treatment and bring hope to those affected by this debilitating disease. [Read more…]

First Patient Dosed with Gamida Cell’s Expanded Cord Blood Cell Therapy, Omisirge™

October 9, 2023 By Cade Hildreth, Founder & President Leave a Comment

Omisirge is the world’s 1st U.S. FDA approved product that is a expanded umbilical cord blood cell therapy.

It is also the only allogeneic stem cell therapy approved by the U.S. FDA on the basis of a global randomized Phase 3 trial.

Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress.

Boston, MA, September 27, 2023 –– Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the first patient has received a stem cell transplant with Omisirge (omidubicel-onlv). [Read more…]

Novo Nordisk Sinks US $136M into Landmark Stem Cell Manufacturing Facility in Denmark

September 30, 2023 By Cade Hildreth, Founder & President Leave a Comment

The Novo Nordisk Foundation will invest up to US$136 million in a new cell therapy manufacturing facility in Lyngby, Denmark.

The Novo Nordisk Foundation is making a substantial commitment of up to DKK 950 million (US $136M) to create an advanced facility dedicated to scaling up cell therapies for use in human patients. This facility, known as the Novo Nordisk Foundation Cellerator, is poised to address a critical gap in the Danish cell therapy ecosystem. Its overarching goal is to facilitate the transition from groundbreaking cell therapy research to tangible treatments for individuals grappling with various chronic diseases such as chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes, and several forms of cancer. [Read more…]

dG Medical Group Launches Regenerative Medicine Program using Mesenchymal Stem Cell Exosomes

September 25, 2023 By Cade Hildreth, Founder & President 1 Comment

Clearwater, FL, September 13, 2023 – dG Medical Group, with a dedication to providing patients, physicians, and clinicians the most advanced and beneficial technology, is launching research studies in the use of Mesenchymal Stem Cell (MSC) Exosomes for a variety of medical conditions. This landmark of an achievement makes it the only product legally permitted to be sold for clinical use through research. [Read more…]

Shoreline Biosciences Smashes Fate Therapeutics and Whitehead Institute in Legal Battle Over iPSCs

September 15, 2023 By Cade Hildreth, Founder & President Leave a Comment

Shoreline Biosciences Wins a Comprehensive Summary Judgment Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use

September 7, 2023, SAN DIEGO – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs), today announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California. [Read more…]